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Occlusion of the renal arteries can threaten the viability of
the kidney when severe, in addition to accelerating
hypertension and circulatory congestion. Renal artery
stenting procedures have evolved from a treatment mainly
for renovascular hypertension to a maneuver capable of
recovering threatened renal function in patients with
‘ischemic nephropathy’ and improving management of
congestive heart failure. Improved catheter design and
techniques have reduced, but not eliminated, hazards
associated with renovascular stenting. Expanded use of
endovascular stent grafts to treat abdominal aortic
aneurysms has introduced a new indication for renal artery
stenting to protect the renal circulation when grafts cross the
origins of the renal arteries. Although controversial,
prospective randomized trials to evaluate the added benefit
of revascularization to current medical therapy for
atherosclerotic renal artery stenosis until now have failed to
identify major benefits regarding either renal function or
blood pressure control. These studies have been limited by
selection bias and have been harshly criticized. While studies
of tissue oxygenation using blood-oxygen-level-dependent
(BOLD) magnetic resonance establish that kidneys can adapt
to reduced blood flow to some degree, more severe
occlusive disease leads to cortical hypoxia associated with
microvascular rarefaction inflammatory injury, and fibrosis.
Current research is directed toward identifying pathways of
irreversible kidney injury due to vascular occlusion and to
increase the potential for renal repair after restoring renal
artery patency. The role of nephrologists likely will focus
upon recognizing the limits of renal adaptation to vascular
disease and identifying kidneys truly at risk for ischemic
injury at a time point when renal revascularization can still be
of benefit to recovering kidney function.
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‘It was the best of times, it was the worst of times, it was
the age of wisdom, it was the age of foolishness, it was the
epoch of belief, it was the epoch of incredulityy’
Charles Dickens, A Tale of Two Cities
Rarely have competing technical advances in medicine, as in
the case of managing renal artery stenosis (RAS) by
endovascular stenting or antihypertensive medical therapy,
become so successful over precisely the same time interval. On
one hand, restoring blood flow to an ischemic kidney beyond
vascular occlusion seems to provide an obvious means to
restore kidney function and improve blood pressure, some-
times significantly. On the other hand, prospective trials
seeking to define the role for renal revascularization up to now
have failed to establish a compelling added benefit for
endovascular stenting when added to effective medical regi-
mens.1,2 Clinicians caring for patients with renovascular
disease understandably find themselves confused by ambi-
guous clinical observations and disappointing results from
prospective randomized trials. Many argue that the trials have
been flawed and potentially misleading.3,4 Issues of patient
selection, statistical quirks, professional bias, and flawed study
designs continue to leave the role of stenting a matter of active
debate and sometimes obscure basic truths that interfere with
optimal patient care. To complicate matters further, newer
aortic procedures for the treatment of abdominal aneurysms
introduce a new potential source of renal artery occlusion that
can threaten kidney viability. The purpose of this review is to
place the role of renal revascularization into context as a tool
for management of atherosclerotic renal disease threatening
renal function and blood pressure control.
PAST: RENAL ARTERY OCCLUSION AS A CAUSE OF
HYPERTENSION
It has been nearly 80 years since landmark studies of
Goldblatt et al.5 and Loesch et al.6 established that sustained
reduction of renal blood flow can raise systemic arterial
pressure. Since then, renovascular occlusion has been among
the most extensively studied forms of experimental
hypertension. Indeed, the premise that signals originating
from the kidney could not only affect urine formation
and solute excretion but could also modify systemic
hemodynamics, endocrine systems, central and peripheral
rev iew http://www.kidney-international.org
& 2012 International Society of Nephrology
Correspondence: Stephen C. Textor, Division of Nephrology and Hyperten-
sion, Mayo Clinic, Rochester, Minnesota 55905, USA.
E-mail: textor.stephen@mayo.edu
Received 26 July 2011; revised 20 July 2012; accepted 27 July 2012;
published online 14 November 2012
28 Kidney International (2012) 83, 28–40
nervous system pathways, vascular structure, cardiac
function, and systemic resistance provides the foundation
for whole systems of understanding of animal and human
physiology.7,8
From a clinical perspective, recognition that reduced renal
blood flow sometimes triggers renovascular hypertension and
can impair glomerular filtration provides a prototype for
‘secondary hypertension’ that can sometimes be ‘cured’ or
‘improved’ after restoring kidney perfusion by revasculariza-
tion. It should be emphasized that before surgical revascular-
ization was technically possible in the 1960s, clinicians had few
effective treatments to reverse malignant phase hypertension.
These sometimes included surgical thoracoabdominal sym-
pathectomy and/or nephrectomy to remove a ‘pressor’ kidney.9
Since then, progress regarding imaging of the vascular
anatomy, identification of pressor hormones from the kidney,
and restoration of blood supply through endovascular
methods has been stunning.10 The ability to safely reach
the vascular bed of major renal arteries and to restore blood
flow allows endovascular intervention for many patients who
would never be considered for open surgical procedures.
Initial renovascular imaging and surgical reconstruction
Vascular surgical techniques in the 1960s developed suffi-
ciently to allow control and successful operative intervention
on the abdominal aorta for acute renal artery occlusion.11
Partly because of these developments, intravascular contrast
agents and vascular imaging became important to establish
the diagnosis and anatomy of vascular disease. Early imaging
of the abdominal aorta was undertaken through translumbar
placement of a needle for contrast injection. Success at
developing flexible catheters that could be introduced via a
guidewire placed into the femoral artery came later and has
been attributed to the successful use of the ‘Seldinger
technique.’12 This was followed by a remarkable series of
technical innovations in catheter design to allow selective
imaging of vascular structures and selective venous sampling,
including measurement of renal vein renin levels.13
Cooperative Study of Renovascular Hypertension
Initial success at surgically restoring renal function after acute
occlusion was followed by attempts to treat RAS to improve
blood pressure control. Detailed studies of individual kidney
function based on measuring inulin clearance and para-
aminohippurate testing could identify when blood flow to
the kidney had been reduced sufficiently to reduce urine flow
and increase sodium reabsorption, but continue to have
glomerular filtration.14 The potential morbidity—and
mortality—associated with renal artery surgery also led to
concerns about the risks of surgical reconstruction and
emphasized the need to carefully select patients who might
benefit. In this context, early studies supported by the
National Institutes of Health were undertaken to define
clinical features, optimal imaging, diagnostic patterns, and
outcomes of surgery for renovascular disease.15–17 This
landmark study provided a registry of more than 500
patients, but was limited by the lack of sampling for
pressor hormones of the renin–angiotensin system. These
studies provided a series of seminal papers regarding clinical
features and comorbidity with atherosclerotic renal arterial
disease.17 These studies also identified a mortality risk above
6% associated with aortic surgery that limited the range of
candidates most centers would consider for surgery.
Renovascular surgery became a highly specialized clinical
skill limited to high-volume centers with focused interest, as
Novick18 reviewed. It remains so today.
RECENT HISTORY: ESTABLISHING THE ROLE OF VASCULAR
OCCLUSION AS A CAUSE OF RENAL INSUFFICIENCY
In view of the complexity and potential risks, the decision to
undertake surgical revascularization routinely included
multiple clinicians, including hypertension specialists, ne-
phrologists, cardiovascular specialists, radiologists, and
surgeons. Determining the likelihood of clinical improve-
ment in blood pressure control was an overriding concern,
more so than any potential recovery of kidney function. In
the 1970s, measurement of the putative pressor signal for
renovascular hypertension, plasma renin activity, became
widely available and led to a series of seminal papers
regarding lateralization of renin secretion from the affected
kidneys,19 contralateral suppression of renin release, and
additional maneuvers to reveal the role of the
renin–angiotensin system for individual patients.20
Early experiences with surgical revascularization cast
doubt that patients with reduced glomerular filtration rate
(GFR) would gain much benefit regarding blood pressure
control from restoring blood supply. Such patients were
routinely excluded from consideration for renovascular
surgery, based on both experimental and clinical data
suggesting that parenchymal damage to the ‘contralateral’
kidney opposite the stenotic kidney would obviate a benefit
regarding blood pressure control.21 Remarkably, the concept
that chronic vascular occlusion might be a reversible cause of
renal insufficiency surfaced only in the 1980s, and was
greeted with skepticism.22,23 Recognition that atherosclerotic
disease poses a risk of progressive vascular occlusion that
could be stabilized or reversed regarding renal failure
gradually led some centers to shift from ‘cure of
hypertension’ to ‘preservation of renal function’ as a
primary indication for revascularization.24,25 Identification
of the concept of ‘critical perfusion pressure’ for continued
renal function that could be reversed by restoring renal blood
flow supported this premise.26 Several authors raised the
possibility that unsuspected atherosclerotic renal arterial
occlusion may contribute to advancing renal insufficiency
more commonly than previously thought and coined the
term ‘ischemic nephropathy.’ 27–31
PRESENT: ENDOVASCULAR RESTORATION OF RENAL BLOOD
FLOW
In 1978, Gruentzig et al.32,33 extended the practice of
peripheral vascular dilation to the kidney in a seminal
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paper on renal artery balloon angioplasty, followed a year
later by a description of initial experience with renal artery
angioplasty in the United States.34 Subsequent reports
confirmed the potential for renal artery angioplasty to
improve management of uncontrolled hypertension.35,36
Technical success for angioplasty was generally good.37 An
obvious major benefit from these endovascular techniques
was the potential for restoring kidney blood flow for many
patients for whom the risks of surgical revascularization
would be otherwise prohibitive.
One shortcoming of renal artery angioplasty was the
tendency for elastic recoil to occur, which narrowed the
lumen again immediately after balloon dilatation. This posed
a major problem for ostial lesions, which usually develop as
an extension of aortic plaque into the renal artery. To prevent
elastic recoil after angioplasty, Palmaz and colleagues in 1987
developed expandable metallic stents for renal arteries in a
porcine model.38 Initial reports of stents being placed in the
renal artery in patients were positive.39,40 These were
followed by evaluation of the Palmaz stent in a clinical
study,41 followed by a randomized trial comparing
angioplasty with stenting that established significantly
higher primary patency rates with the use of stents.42
Today, primary stent placement for ostial RAS has become
the standard (Figure 1a and b).
Since the original description of the procedure, additional
improvements in the technology have occurred, including the
development of low-profile catheters and semicompliant
balloon technology.43 The original balloon catheters were
constructed on a larger platform (0.038 inches), but are
currently being delivered using smaller (0.014 inches)
guidewire technology. These lower-profile catheters help
reduce periprocedural complications including embolization
and vessel dissection that can occur during the introduction
of the stent across the stenosis.
Restenosis of treated vessels has been a practical limita-
tion. Typically, one renal artery supplies each kidney and
most renal arteries are 5mm in diameter or larger. A recent
study using computed tomography angiography of the renal
arteries demonstrated that 30% of patients have more than
one renal artery supplying each kidney and that the average
renal artery diameter is 5.6 to 6.0mm.44 Restenosis rates for
stents placed in vessels 45mm in diameter are 15–20% at 9
months when measured by duplex ultrasound.45,46 Target
vessel restenosis warranting reintervention for clinical
indications such as recurrent hypertension, deteriorating
kidney function (rise in creatinine by more than 20%), or
recurrent pulmonary edema developed in 88 of 877 arteries
(10.0%) from 748 patients followed longitudinally for a mean
of 46 months.47 Vessels o5mm were twice as likely to
restenose as compared with larger vessels.48 Other predictors
for restenosis include advanced age, a solitary functioning
kidney, and extensive peripheral vascular disease. Restenosis
for symptomatic patients after stent placement can be treated
by restenting or with angioplasty. Newer technologies
continue to be developed, such as drug-eluting stents
(DESs), drug-coated balloons, and cutting balloons.49–51
DESs have been available to treat coronary arteries since
early 2000.52 The major advantage of DESs is reduced risk for
restenosis when compared with bare-metal stents,
particularly in smaller vessels. Several groups have used
DESs in small-diameter vessels such as accessory renal
arteries, and some have observed patency rates of 70% in
an average vessel diameter of 3.5mm as compared with 47%
with bare-metal stents.53 Some trials have not observed major
benefits from DESs.54,55
Complications of renal stenting
Despite major technical improvements, periprocedural com-
plications during renal artery stent placement can be
problematic, especially in the presence of a diseased aorta.
These include atheroembolism, renal artery or aortic
dissection, renal artery rupture, and contrast-induced
nephropathy (CIN).
Atheroembolism typically occurs during the manipulation
of the catheter while selecting and engaging the renal artery or
while advancing the stent across the stenosis.56 As a preventive
measure, embolic protection devices (EPDs) created for
saphenous bypass grafts for coronary artery disease or
carotid artery stenosis57–60 have also been applied in
conjunction with renal artery stent placement.61–68 Currently,
there are many different EPDs that can be used to prevent
embolization during the placement of stents in the renal artery.
To improve selection of a specific EPD, computed
tomography angiographic studies were applied to examine
design criteria based on the diameter and length of the renal
arteries. Some devices (including SpideRx, Angioguard, and
Accunet) had more favorable characteristics for arteries with
a diameter of 4–8mm and a stent length of 12mm in order to
L
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Figure 1 | Angiographic images before and after renal artery
stenting. (a) Guidewire placement beyond a high-grade proximal
stenosis. (b) Stent deployed with filter-wire embolic protection device
(EPD), shown after removal in (c). Embolic debris is visible in the distal
section of the EPD.
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meet needed diameters for introduction and size with an
adequate ‘landing zone’ before renal artery bifurcation.44
Single-arm observational studies using EPD report recovery
of embolic debris and kidney function stabilization after
revascularization.62–68 Most of these reports indicate
stabilization or improvement of kidney function in 80–93%
of the patients after the procedure with variable capture rates
of atheroembolic debris (Figure 1c).61 It should be
emphasized that the only prospective, randomized trial of
EPD with renal stent placement demonstrated no difference
between renal functional outcomes with or without the use of
the Angiogard.69 This study used a device with a large profile
that could itself cause thrombus formation during the
procedure (Angioguard). This device was eventually
removed from use in the CORAL trial owing to its
tendency to injure renal vessels. Remarkably, there appeared
to be an interaction between platelet inhibition using
abciximab and the EPD, favoring the combination above to
either specific measure alone. Clinical observations indicate
that atheroemboli sometimes develop in the days and weeks
after the procedure,70 limiting the clinical value of EPDs
deployed only during the stenting procedure itself.
Additional complications during renal artery stent place-
ment include dissection, renal artery rupture, and CIN. The
reported cumulative risk of arterial dissection or rupture is
o4%, often treated with prolonged angioplasty or covered
stent, respectively.71 CIN occurs in o5%. N-acetylcysteine
(Mucomyst1; Bristol Myers Squibb, Anagni, Italy) at a dose of
600mg twice daily for 2 days can be given safely to reduce
CIN.72 Sodium bicarbonate has also been advocated to
reduce the risk of CIN. Alternative contrast agents such as
carbon dioxide are available, but image quality is not as good
as conventional contrast agents. Patients commonly receive
325mg of aspirin the day before the procedure. In patients
with atherosclerotic renal artery stenosis, 300mg clopidogrel
(Plavix; Bristol-Myers Squibb, New York, NY) is initiated the
day before the procedure and 75mg on the day of the
procedure. Patients who receive stents commonly are
maintained on 325mg aspirin for life and 75mg Plavix for
1–3 months.
Renal functional outcome after renal artery stenting
Reports from several small studies indicate that renal artery
stent placement in some patients undergoing hemodialysis
sometimes allows recovery of kidney function to such an
extent that they no longer require dialysis.73–77 These
observations indicate that some individuals certainly obtain
a major clinical benefit from successful stenting, as illustrated
in Figure 2a and b. Selection of patients for intervention
remains highly controversial. How many patients reaching
advanced renal insufficiency, even in the presence of large-
vessel occlusive disease, do so on the basis of impaired
vascular supply is unknown. Many series of patients with
various levels of renal dysfunction report little change on
average after technically successful revascularization.78
Although some reports present predictors of benefit, many
of these suffer from relatively imprecise outcome
definitions.79–82
Observational reports most commonly include average
levels of GFR (based on creatinine equation estimates such as
MDRD (Modification of Diet in Renal Disease) estimated
GFR). Most often, average GFR for the entire group changes
little during follow-up intervals as long as several years. Within
these reports, series with renal insufficiency and solitary
kidneys often identify some individuals who reverse the trend
to progressive renal failure.83,84 In some reports, this is as
many as 67% of subjects with creatinine values 41.5mg/dl
and stenosis affecting the entire renal mass.78 Recovery of renal
function in such patients offers a major benefit in terms of
both blood pressure control and survival (Figure 2b). When
one expresses clinical results as ‘improved’ or ‘stabilized,’
nearly all report at least 60% in these categories.73,85–87 Most
reports agree that a recent deterioration in kidney function is
among the strongest predictors of likely recovery after
endovascular repair.88,89 Patients with continued progression,
despite technically successful revascularization, commonly
reach end-stage renal disease. In nearly all reported series, a
subset of patients progresses to advanced renal failure despite
technically successful stenting.90
Renal artery revascularization has limited benefits for
patients with established long-term loss of GFR.1,91 Results
from studies of late-outcome data in 550 patients treated at
Mayo Clinic with renal artery stenting for either uncontrolled
hypertension or worsening renal function indicate that
established low levels of estimated GFR indicate progres-
sively worse renal outcomes for stage 4 and 5 chronic kidney
disease. Renal outcomes including subsequent freedom from
dialysis and/or transplantation were established by querying
the United States Renal Data Systems Database. The mean
pretreatment estimated GFR in this group overall was
34±13ml/min per 1.73m2 (MDRD; Figure 3) Not surpris-
ingly, these data confirm that pretreatment levels of kidney
function portend major differences in long-term clinical
outcomes and argue for careful identification and selection of
patients for revascularization before far advanced loss of
GFR. Even with technically successful revascularization,
advanced chronic kidney disease tended to progress for
many patients in this cohort.
Present-day dilemmas: evidence for and against
revascularization in the era of effective medical therapy and
highly prevalent atherosclerotic RAS
Recent series for which imaging of the renal arteries is
included as part of the evaluation of other vascular beds
confirm that atherosclerosis is often widespread, with
prevalence of visible occlusion (often taken as 50% lumen
occlusion) rising from 10 to 14% for individuals with
‘suspected’ renovascular hypertension to 435% for indivi-
duals with abdominal aortic disease.92 These figures are far
higher than estimates in the hypertensive population at
large, for which most authors argue that no more than
1–2% of hypertensive individuals have ‘true renovascular
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hypertension’ (defined in retrospect as a ‘cure’ after successful
revascularization).93 Advances in antihypertensive drug
therapy now allow more patients to achieve acceptable
blood pressure levels than before. A working classification of
renal arterial disease based upon the functional role related to
blood pressure and renal function is summarized in Table 1a
and b. Some authors suspect that a sizable fraction of
unexplained renal dysfunction, circulatory congestion (for
example, refractory heart failure), and other cardiovascular
morbidity may be related to this disorder.94,95 Observational
series conclude that many patients have improved clinical
outcomes regarding cardiovascular events, even mortality,
after successful renal revascularization.96,97 Position papers
from some professional organizations support these
positions,98 although they have been questioned by
others.99 These trends led to the expansion of renal artery
revascularization.100 Within the United States, application of
endovascular procedures for renal arterial disease in the
Medicare population alone rose more than fourfold in the
decade between 1996 and 2005.101 Endovascular stenting of
the renal arteries has become the primary procedure for
revascularization for atherosclerotic disease. Surgical bypass
procedures have declined substantially over the same
interval.102
Serum creatinine at end of follow-up
Source
SNRASCG
ASTRAL
NITER
STAR
–2
5.0
Fall 1.0 mg/dl
n=83 (27.3%)
Same (Δ <1.0 mg/dl)
n=160 (52.6%)
Rise 1.0 mg/dl
n=61 (20.1%)
5.0
6.0
7.0
4.5
4.0
4.0
3.0
3.5
2.5
2.0 2.0
2.2
2.4
2.6
2.8
3.0
2.0
Preop LFU Preop LFU Preop LFU
3.0
–1 0
Favors
percutaneous
revascularization
Favors
medical
management
1 2
–0.16 (–0.63, –0.31)
Weighted mean
difference (95% CI)
Percutaneous
intervention
Medical
therapy
Mean (s.d.)
–0.14 (–0.29, 0.01)
–0.08 (–0.37, 0.53)
1.9 (0.9)
1.9 (0.9)
1.8 (0.8) 1.9 (0.9)
1.8 (0.8)
2.4 (1.6)
2.0 (0.9)
2.2 (1.4)–0.21 (–0.42, 0.00)
–0.10 (–0.37, 0.17)
Overall (95% CI)
Test for heterogeneity: l2 = 0%
Test for overall effect: P = 0.06
Figure 2 | Clinical outcomes of renal artery revascularization for atherosclerotic renal artery disease. (a) Meta-analysis of four randomized
controlled trials evaluating serial measurements of creatinine in patients treated either with angioplasty (SNRASG) or angioplasty and stenting.
Mean values did not change during the follow-up periods reported. A subgroup of 20–28% of subjects were not revascularized in ASTRAL or
STAR as assigned, mainly because of finding only trivial stenoses at the time of angiography (see text). Reproduced from Kumbhani et al.105
with permission. 95% CI, 95% confidence interval. (b) Serum creatinine levels before and after renal revascularization (mean follow-up (f/u) 28
months) in 304 subjects with initial serum creatinine level42.0mg/dl. These data underscore the differences with subgroups that are masked
by group averages, which did not change overall. It should be emphasized that all of them underwent revascularization based upon clinician
judgment as to the likely benefit and were not randomized. A fall of41.0mg/dl was considered to be a meaningful decline, which occurred in
27.3% of this group (left panel). Most had little change (middle panel), but slightly more than 20% of patients whose creatinine rose with
significant deterioration of kidney function experienced a rise of41.0mg/dl. Nearly all series of results from endovascular or surgical revascula-
rization contain some variation of these patterns, partly dependent on the starting level of glomerular filtration rate (GFR), and the degree of
change in kidney function deemed significant. Some of the loss of GFR is probably related to atheroembolic complications, which may be less
common than before, which is partly related to improved technical expertise (see text). Reproduced from Textor and Wilcox151 with permission.
LFU, last follow-up value; Preop, preoperative value.
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A review of the expansion of endovascular stenting
commissioned by the Centers for Medicare and Medicaid
Services (CMS) in 2007 questioned the strength of evidence
for this practice.103 During roughly the same period, more
widespread application of modern antihypertensive drug
therapy—including agents that block the renin–angiotensin
system and calcium channel blocking agents, management
of atherosclerotic disease with statins, aspirin, and with-
holding tobacco use—was taking hold. Several small,
prospective trials comparing medical therapy with or
without either surgical or endovascular procedures to
restore renal blood flow fail to demonstrate major
advantages to renal revascularization up to now, as we
and others have reviewed.104,105 These trials have been
small, conducted over short intervals, and have been
ferociously criticized on methodological grounds.3,106 Most
of these trials had profound challenges in recruiting, partly
because of the established patterns, experience, and beliefs
summarized above. Nevertheless, widespread application
of renal artery stenting has been declining in recent years,
mainly because of the negative results from these trials.
APPEARANCE OF A NEW INDICATION FOR RENAL ARTERY
INTERVENTION: ENDOVASCULAR AORTIC REPAIR AND
RENAL FUNCTIONAL OUTCOMES
Current estimates indicate that up to 15,000 abdominal
aortic aneurysms may rupture annually.107 Traditionally,
these patients have been treated by open surgical repair, with
an average operative mortality of 4% in the largest reports.108
Endovascular aortic aneurysm repair (EVAR) has gained
widespread acceptance for the treatment of infrarenal aortic
aneurysms, but offers potential hazards regarding the
development of renal arterial obstruction. Results from
prospective randomized studies confirm that EVAR reduces
operative time, blood loss, transfusion requirements, hospital
stay, morbidity, and mortality compared with open surgical
repair.109,110 A critical requirement for successful EVAR is the
presence of sufficient length of normal aorta (for example,
aortic neck) to provide adequate proximal and distal fixation
to the endograft and to seal the aneurysm sac. Many stent
grafts are placed in close proximity to the origins of the renal
arteries. In some patients with short infrarenal necks or more
extensive aneurysms, the renal arteries may be deliberately
included in the repair, with provision for placement of a
protective renal artery stent through fenestrations or side
cuffs, which are customized to the patient’s anatomy
(Figure 4a and b).
Preservation of renal artery patency during EVAR is
critical for several reasons. A postprocedural decline in renal
function is associated with increased mortality.111,112
Although a modest decline in renal function commonly
occurs after EVAR approaches 1ml/min per 1.73m2 per year
(typical of an aging population), more significant
deterioration in renal function can develop, which is asso-
ciated with inadvertent renal artery occlusion, renal artery
complications (stenosis, plaque dislodgement or dissection),
and the use of fenestrated endografts.113 Haddad et al.114
reported that 23 of 72 patients (32%) treated with fenestrated
endografts for juxtarenal aneurysms had 430% decline in
GFR, although the majority recovered by 6 months. Results
from another prospective nonrandomized study of 287
patients treated by fenestrated endografts indicate that renal
function deterioration occurred in 20% and was associated
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Figure 3 | Kaplan–Meier plots of freedom from requiring renal
replacement therapy for 550 patients with variable pretreatment
levels of estimated glomerular filtration rate (GFR) after
technically successful renal artery angioplasty and stenting.
Follow-up data were verified through the United States Renal Data
System (USRDS). These data argue that advanced loss of GFR
portends eventual progression to end stage regardless of restoring
renal artery patency.
Table 1 | Clinical classification and recommendations for
management of renal artery stenosis
(a) Functional classification for atherosclerotic renal artery stenosis
Grade I: Renal artery stenosis present, but no clinical manifestations
(normal blood pressure and normal renal function).
Grade II: Renal artery stenosis present, but patients have medically
controlled hypertension and normal renal function.
Grade III: Renal artery stenosis present and patients have evidence of
abnormal renal function, medically refractory hypertension, or evidence
of volume overload.
(b) Factors favoring medical therapy and revascularization for renal artery
stenosis
Progressive decline in GFR during treatment of hypertension.
Failure to achieve adequate blood pressure control with optimal
medical therapy.
Rapid or recurrent decline in the GFR in association with a reduction in
systemic pressure.
Decline in GFR during therapy with ACE inhibitors or ARBs.
Recurrent congestive heart failure in a patient in whom the adequacy
of left ventricular failure does not explain the cause.
Factors favoring medical therapy and surveillance of renal artery disease
Controlled blood pressure with stable renal function.
Stable renal artery stenosis without progression on surveillance studies
(e.g., serial duplex ultrasound).
Advanced age and/or limited life expectancy.
Extensive comorbidities that make revascularization too risky.
High risk or previous experience with atheroembolic disease.
Other concomitant renal parenchymal diseases that cause progressive
renal dysfunction (e.g., diabetic nephropathy).
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor
blocker; GFR, glomerular filtration rate.
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with the presence of RAS or kidney infarcts because of
intraprocedural embolization or coverage of early branch
bifurcations or accessory renal arteries by the stent graft.115
Several factors likely contribute to renal injury observed in
some patients undergoing EVAR, including exposure to
repeated doses of contrast agents, implantation of stent
grafts, and follow-up surveillance imaging. Endovascular
aortic instrumentation carries particular risk of atheroembo-
lization, particularly for patients with complex aneurysms
and thrombus involving the renal arteries or those who need
adjunctive renal artery stenting. Implantation of fenestrated
endografts that cover the renal arteries and require placement
of adjunctive renal artery stents can be technically challeng-
ing. These grafts are associated with higher rates of potential
renal artery dissection and/or perforations compared with
renal artery stent placement performed alone for occlusive
disease.114–116
ADJUNCTIVE RENAL ARTERY STENTS DURING EVAR
Inadvertent coverage of the renal arteries is described in 0 to
6% of patients undergoing EVAR.109,110,113,117–119 When
identified and treated immediately by placement of a renal
stent, this results in minimal adverse sequelae. However,
introduction of renal stents in patients with suprarenal
fixation can be difficult and may require the use of a stiff
guidewire system and large platform to provide enough
support.118 If renal artery impingement is not promptly
recognized and treated, renal artery occlusion is a frequent
complication.117
Some aortic endografts use deliberate suprarenal fixation
with an uncovered stent that extends above the renal arteries
designed to improve fixation into the normal aorta and
prevent distal migration. The presence of a suprarenal
fixation structure may complicate subsequent placement of
renal artery stents because of stent struts crossing the
renal artery ostia, thereby encroaching on the renal artery
lumen. These may limit the effective achievable renal
blood flow or the cross-sectional luminal area.117,120–122
Despite theoretical concerns that suprarenal fixation may
impair renal function, results from experimental studies and
clinical reports that compare infrarenal versus suprarenal
fixation stents during EVAR identify only minor differences
between these stent designs. Nevertheless, suprarenal
fixation inevitably makes placement of renal artery stents
more challenging in some patients, mainly as a result of
adding difficulty in selective catheterization of the renal
arteries, advancement of the sheath or guide catheter, and
expansion of the stent, which can be partially compressed by
the suprarenal stent.118,119
Prior placement of renal artery stents can limit
suitability for the treatment of the aneurysm using
endografts. Because a renal artery stent is typically placed
a few millimeters into the aorta, aortic grafts with
suprarenal fixation or fenestrated stent grafts that extend
above the renal arteries may no longer achieve adequate
implantation. These are important considerations when
deciding the timing and sequence of repair in patients who
have aortic aneurysms and renal artery disease that
warrants revascularization.
Recent developments include wider application of ‘fene-
strated’ stent grafts with construction of grafts to protect
renal and mesenteric vessels (Figure 4b). Migration is a rare
occurrence given that these customized endografts have
excellent fixation and are designed to be implanted in normal
aorta. Renal artery stent patency for patients with fenestrated
aortic stent grafts averages 95% at 5 years in patients, higher
than that reported for renal artery stents performed for
occlusive disease.123–128 In-stent stenosis affected the
proximal portion of uncovered stents, whereas stenosis
observed in covered stents affected the distal edge of the
stent. Renal artery stent occlusion rate was 4.5% for
uncovered stents and 2.2% for covered stents, and
cumulative incidence of new permanent dialysis was 2% for
the entire cohort.
D.F.
©MAYO
2009
Figure 4 | Endovascular aortic grafts as a cause for renal artery
obstruction. (a, b) Computed tomography (CT) angiogram of
endovascular stent graft placed above the renal arteries. Renal artery
stents are placed through the graft struts to maintain renal artery
patency, although some deterioration of kidney function and/or
embolic injury can occur.
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THE FUTURE FOR RENAL ARTERY STENTING: PATIENT
SELECTION: AMBIGUITY AND ‘EVIDENCE-BASED MEDICINE’
Despite major successes in selected individual cases, persua-
sive evidence of benefit for many patients from renal
revascularization has been lacking.101 Several limited,
prospective, randomized controlled trials for patients with
atherosclerotic RAS have been undertaken within the past 7
years to examine the benefit of renal artery stenting when
added to current medical therapy. Major features of these
trials are summarized in Table 2. The numbers of subjects,
age, levels of kidney function, and selection criteria have been
highly variable. None of these trials provided strong results
supporting recovery or preservation of renal function.
Remarkably different statistical power estimates were used
to define the number of subjects needed to identify clinical
events, ranging from o100 to nearly 1000 participants.103,104
Clearly, the investigators anticipated widely different rates of
outcome events and disease progression, reflecting the
inaccuracies of using historical data and selected patient
series.129 Many authors emphasize the heterogeneity between
patients with widespread atherosclerosis and the comorbid
disease risks that affect outcomes in this population
independent of renovascular disease. Some have argued that
the complexity of these confounders render patients so
heterogeneous that meaningful prospective trials are
practically impossible.130 It is important for clinicians
evaluating these trials to recognize that entry criteria for
many of these trials were based on marginally significant
vascular occlusion for many participants. In the STAR trial,
for example, 28% of patients assigned to stenting were not
treated, mainly because only trivial stenoses were found at the
time of angiography.131 Recent studies further challenge the
premise that estimated GFR methods can identify changes in
kidney function accurately in patients with RAS in the 20%
range applied to recent trials.132 Some of the major limitations
of these trials are summarized in Table 3.
The most carefully performed of these trials to date is the
US-based Cardiovascular Outcomes for Renal Arterial
Lesions (CORAL) supported by the NHLBI (National Heart,
Lung, and Blood Institute). This trial has enrolled 947
subjects and randomized them to protocol-based antihyper-
tensive and atherosclerotic medical therapy with or without
renal artery stenting. Although investigators participating in
this trial have taken care to assure that subjects have
hemodynamically significant renovascular disease, how these
enrollees will compare with the many thousands of patients
not enrolled will be difficult to ascertain.
Table 2 | Baseline characteristics of prospective, randomized treatment trials comparing medical therapy with or without renal
artery intervention (PTRA with or without stents)
EMMA SNRASCG DRASTIC ASTRAL STAR NITER
Location France UK The Netherlands UK/Aust/NZ The Netherlands Italy
Year 1998 1998 2000 2009 2009 2009
No. of Pts (Intervent./Med Rx) 23/26 25/30 56/60 403/403 64/74 28/24
Mean age (years) 59.4 61.1 59.9 70.5 66.5 72.0
CAD (%) NA NA NA 48.5 39.3 63.5
ASPVD (%) NA NA NA 40.5 40.0 46.2
Creatinine baseline (mg/dl) 1.2 1.8 1.3 2.0 1.7 1.7
Bilat (%) 0 50.9 22.6 53.5 47.9 51.5
ACE/ARB at F/U (%) NA 0 NA 45 57 61
Crossover (%) 26.9 6.2 44 3.2 1.3 0
F/U mean (months) 6 12 12 33.6 24 43
Comment: Entry criteria ‘Unilateral only’ ‘Resistant HTN’ ‘Resistant HTN’ ‘Uncertainty of benefit’ ‘Renal insufficiency’ ‘Resistant HTN/CRI’
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; ASPVD, atherosclerotic peripheral vascular disease; Aust, Australia; Bilat, bilateral;
CAD, coronary artery disease; CRI, chronic renal insufficiency; F/U, follow-up; HTN, hypertension; Intervent., intervention; Med Rx, medical therapy; NA, not applicable; NZ,
New Zealand; PTRA, percutaneous transluminal renal angioplasty; Pts, patients.
None of these trials identified a meaningful benefit regarding changes in kidney function (see text and Figure 2). These were combined into a meta-analysis including
B1200 patients. Baseline assumptions regarding the risk of progression, diagnostic features, medications, and follow-up differed substantially (see text). Two trials of renal
function (ASTRAL and STAR) failed to revascularize 20–28% of subjects mainly because of minimal lesions identified at angiography.
Modified from Kumbhani et al.105
Table 3 | Limitations of clinical trials in atherosclerotic renal
artery stenosis
1. Patient selection
a. Most severe cases not considered for randomization.
b. Most severe hypertension and progressive renal disease not
included.
c. Limited selection of antihypertensive drug therapy.
i. Role of renin–angiotensin system blockade.
ii. Nonstandardized measurement of outcomes: blood pressure (BP)
levels.
d. Nonstandardized therapy for dyslipidemia/comorbid disease.
2. Outcome measurement
a. Widely variable definitions of BP goals, achieved levels.
b. Variable measurement of renal function.
c. Circulatory congestion/volume control/drug selection.
d. Crossovers from medical to interventional arms: 20–44%.
e. Short duration of follow-up.
3. Confounders limiting interpretation
a. Roles and magnitude of comorbid disease: diabetes, preexisting
cardiovascular disease.
b. Age/timing of intervention/timing of detection of disease.
c. Intermixing degree of renal involvement/tissue at risk: roles of
unilateral and bilateral disease unevenly addressed.
d. Rates of development of disease, including renal dysfunction/BP
changes.
e. Definition of treatment ‘resistance.’
Modified from Textor et al.104
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Whether randomized controlled trials are truly appro-
priate for this condition and/or will provide meaningful
guidance is not clear. In some respects, relying upon medical
therapy alone to lower systemic arterial pressures in the face
of deteriorating kidney function beyond a critical stenosis has
flawed ‘face validity.’ Further reduction of renal perfusion
beyond a ‘critical’ level obviously threatens the viability of the
kidney. Some authors argue that depending upon rando-
mized controlled trial data in this disorder is akin to arguing
for a controlled trial of parachutes133 or bulletproof vests.4
The parachute analogy seems particularly apt, as some argue
that the spectrum of renovascular disease truly includes a full
range comparable to testing efficacy of parachutes for
jumping from a footstool (no benefit) to jumping from a
second-story window (unknown, equipoise) to jumping from
an airplane at 10,000 feet (near certain benefit, prospective
trial not ethical).4
What to do? Limits to adaptation of reduced blood flow in
the kidneys
An important recent observation in renovascular disease is
that gradually developing vascular occlusion leads to
‘adaptation’ that protects intrarenal oxygenation for many
subjects. Studies of tissue deoxyhemoglobin within the
kidney using blood-oxygen-level-dependent magnetic reso-
nance demonstrate complex adaptive processes that prevent
hyperoxia in the renal cortex—and thereby minimize
generation of toxic reactive oxygen species—and at the same
time preserve oxygenation both between the cortex and the
medulla despite substantial reductions in blood flow and
GFR134 (Figure 5). Sudden loss of renal perfusion regularly
produces acute hypoxia and kidney injury.135,136 Gradual
reduction of blood flow over the years, however, more often
leads to reduction in blood flow with preservation of oxygen
levels and metabolic activity. Experimental studies confirm
that medullary blood flow can be regulated independently of
cortical hemodynamics, partly by modifications of changes in
energy-dependent oxygen consumption, reduced filtration,
and changes in arteriovenous shunting.137 These observations
partly explain the relative stability of kidney function and the
lack of progressive renal injury in many patients treated
medically, as observed in the ASTRAL trial.138
It is equally clear, however, that renal adaptation has
limits. When occlusive vascular disease reaches some ‘critical’
level—perhaps based upon severity or duration—adaptive
processes are overwhelmed and cortical hypoxia is apparent
(Figure 5). Progressive renal damage ensues with micro-
vascular ‘rarefaction’ and activation of inflammatory and
Stenotic kidney Contralateral kidney
Figure 5 | Blood-oxygen-level-dependent (BOLD) magnetic resonance (MR) images with parametric maps depicting R2* levels that
correspond to tissue levels of deoxyhemoglobin in axial images of the kidneys. Both of these kidneys had high-grade renal arterial
stenosis with velocities4400 cm/s. Serum creatinine was43.6mg/dl, although the patient was treated with angiotensin receptor blockers and
diuretics. The larger kidney (right panel, left kidney) has well-preserved cortical oxygenation (blue zone) and a normal corticomedullary oxygen
gradient. The smaller kidney (left panels) is developing overt cortical hypoxia with rising R2* levels and expanding zone of medullary hypoxia
(inner red zone). These functional imaging tools may assist in defining kidneys that are ‘at risk’ from critical vascular occlusion, yet remain
‘salvageable’ from the point of view of restoring renal blood flow (see text).
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fibrogenic processes.139,140 At some point, the viability of the
poststenotic kidney is lost entirely.
Improving renal recovery
Is it possible that ‘adjunctive’ measures, such as administra-
tion of specialized cells or cytokines and/or denervating the
kidneys, beyond simply restoring blood flow can boost the
recovery of kidney function? In some cases, injury to kidney
tissue may be magnified by ‘ischemia/reperfusion’ injury with
release of reactive oxygen species or mitochondrial injury
related to flooding ischemic tissue with oxygenated
blood.141,142 Atheroemboli continue to be a major concern,
and may develop in nearly all vessels subjected to instrumen-
tation.56 A worrisome observation from both observational
and randomized controlled trials is that restoring blood flow
alone infrequently leads to full recovery of kidney function.
Experimental data in a swine model indicate that endothelial
progenitor cell infusion can boost restoration of the renal
microvessels and facilitate repair of renal parenchymal
structures.143 Studies using intrarenal administration of
mesenchymal stem cells suggest that cell-based therapy can
result in improved recovery of microvascular function.144
Recent studies using radiofrequency ablation of vascular
nerve bundles alongside the renal arteries raise the possibility
that both afferent and efferent adrenergic signals may affect
kidney function as well as blood pressure regulation.145 A
broad literature supports the notion that renal nerve traffic
modulates renin release, blood flow, and tubular function,
and can modify central nervous system signals affecting the
circulation.146–148 Some of these signals are changed after
endovascular revascularization alone.149 Up to now, studies
of endovascular renal denervation have excluded subjects
with primary renovascular lesions, specifically to avoid the
question of whether such procedures induce renovascular
injury. Some might argue that combining restoration of
blood flow with interruption of renal nerve traffic may
magnify potential clinical benefits of either treatment.
Whether these measures will extend to human renal
revascularization procedures and improve the potential for
restoring lost renal functional capacity is not known.
Nephrologists and renal revascularization in the future
Clinicians caring for patients with renovascular disease
should recognize that restoring blood flow is critical for
some individuals. As a practical matter, clinicians must
evaluate individual patients carefully—and repeatedly—to
decide about the relative merits of relying on medical therapy
or adding renal revascularization. We favor using the general
guidelines summarized in Table 1b, as they apply to a specific
patient over time. The challenge for nephrologists is to
identify patients whose kidneys are truly at risk from vascular
occlusion at a point when restoring blood flow may still
improve the outcome. Defining such patients remains
difficult. Whether advances in imaging, evaluating oxygena-
tion, and/or identifying injury pathways will allow for more
precise diagnosis and the role for stenting remains to be seen.
The limitations of trial data notwithstanding, current
published studies in the general medical literature identify
‘substantial risks, but no evidence of a worthwhile clinical
benefit from revascularization in patients with atherosclerotic
renal artery stenosis.’138 Hence, the pendulum that led
initially to excessive enthusiasm for renal revascularization
appears to have swung to the opposite extreme. Clinicians are
aware of the fact that ‘average’ values may obscure important
individual differences in clinical trials.150 We anticipate—and
have already encountered—some patients managed solely
with medical therapy until advanced loss of renal function
occurs. Our contention is that clinicians—including
nephrologists and cardiovascular specialists—will need to
be more vigilant to recognize the potential for recovery and/
or stabilization of renal viability and blood pressure control
than before. It will likely fall more on subspecialists in
vascular medicine and nephrology to advocate for restoring
blood flow and preventing kidney injury when possible.
Developing more effective tools to identify viable kidneys
and/or those at risk from irreversible vascular injury remains
a top priority in this field.
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